Literature DB >> 2318454

A comparative study of computerized tomography, magnetic resonance imaging, and clinical staging for the detection of early cervix cancer.

M Brodman1, F Friedman, P Dottino, C Janus, S Plaxe, C Cohen.   

Abstract

Sixteen patients with cervical cancer underwent radical surgery following standard clinical staging, MRI, and CT. The sensitivity of the CT scan was 14%, the specificity 100%. MRI had a sensitivity of 28% and a specificity of 64%. The clinical stage was correct in 10 of 16 patients (62%). CT and MRI are not individually or collectively better than clinical staging in predicting extent of disease, and currently should not be included in the FIGO staging for cervix cancer.

Entities:  

Mesh:

Year:  1990        PMID: 2318454     DOI: 10.1016/0090-8258(90)90153-c

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Comparison of Computed Tomography- and Magnetic Resonance Imaging-based Clinical Target Volume Contours at Brachytherapy for Cervical Cancer.

Authors:  Cameron W Swanick; Katherine O Castle; Sastry Vedam; Mark F Munsell; Lehendrick M Turner; Gaiane M Rauch; Anuja Jhingran; Patricia J Eifel; Ann H Klopp
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-07-30       Impact factor: 7.038

2.  Computed Tomography-Guided Interstitial Brachytherapy for Locally Advanced Cervical Cancer: Introduction of the Technique and a Comparison of Dosimetry With Conventional Intracavitary Brachytherapy.

Authors:  Zhong-Shan Liu; Jie Guo; Yang-Zhi Zhao; Xia Lin; Bing-Ya Zhang; Chu Zhang; Hong-Yong Wang; Lei Yu; Xiao-Jun Ren; Tie-Jun Wang
Journal:  Int J Gynecol Cancer       Date:  2017-05       Impact factor: 3.437

3.  CT based three dimensional dose-volume evaluations for high-dose rate intracavitary brachytherapy for cervical cancer.

Authors:  Naoya Murakami; Takahiro Kasamatsu; Akihisa Wakita; Satoshi Nakamura; Hiroyoki Okamoto; Koji Inaba; Madoka Morota; Yoshinori Ito; Minako Sumi; Jun Itami
Journal:  BMC Cancer       Date:  2014-06-17       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.